2009;2:287 93. 61. Stienen S, Salah K, Moons AH, et al. Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a pre- defined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes. Am Heart J. 2014;168:30 6. 62. Stienen S. PRIMA II: can NT-pro-brain-natriuretic peptide (NT-proBNP) guided therapy during admission for acute heart failure reduce mortality and readmissions? J Card Fail. 2016;22:939 40. 63. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart fail- ure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071 8. management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344 426. 65. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac tro- ponin T using a highly sensitive assay in patients with chronic heart fail- ure: data from 2 large randomized clinical trials. Circulation. 2012;125: 280 8. 66. Savarese G, Musella F, D'Amore C, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta- analysis. J Am Coll Cardiol HF. 2014;2:148 58. 67. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309:2262 9. 68. de Boer RA, Daniels LB, Maisel AS, et al. State of the Art: Newer biomark- ers in heart failure. Eur J Heart Fail. 2015;17:559 69. 69. Gopal DM, Sam F. New and emerging biomarkers in left ventricular sys- tolic dysfunction insight into dilated cardiomyopathy. J Cardiovasc Transl Res. 2013;6:516 27. 70. O'Meara E, de DS, Rouleau JL, et al. Circulating biomarkers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep. 2013;10:350 8. 71. 